期刊文献+

穴位注射对椎动脉型颈椎病ET、CGRP影响及疗效观察 被引量:10

Observations on the Influence of Point Injection on ET and CGRP in Vertebral Artery-type Cervical Spondylopathy and Its Therapeutic Effect
下载PDF
导出
摘要 目的观察颈夹脊穴位注射治疗椎动脉型颈椎病(CSA)的疗效,并探索血管内皮素(ET)、降钙素基因相关肽(CGRP)在CSA发病中的变化情况及意义。方法随机将60例椎动脉型颈椎病患者分成颈夹脊穴位注射组(治疗组)30例和电针组(对照组)30例,用放射免疫法分别检测60例CSA患者治疗前后血浆ET、CGRP的变化。结果治疗组总有效率为96.7%,对照组总有效率为93.3%。治疗前两组患者的血浆ET含量高于正常参考范围,CGRP含量低于正常参考范围,治疗后血浆ET含量有所下降,CGRP含量明显升高,与治疗前比较差异具有统计学意义(P<0.05)。结论ET、CGRP在椎动脉型颈椎病发病中可能起重要的神经体液调节作用;颈夹脊穴位注射能更有效地降低血浆ET含量,升高血浆CGRP的含量,扩张椎动脉内径,改善椎动脉的血流状况。 Objective To investigate the therapeutic effect of point injection on cervical spondylopathy of vertebral artery type(CSA) and explore changes in ET and CGRP during its development and their significances.Methods Sixty patients with vertebral artery-type cervical spondylopathy were randomly allocated to a cervical jiaji point injection group of 30 cases and an electroacupuncture group of 30 cases as a control.Serum ET and CGRP were measured by radioimmunoassay in the 60 CSA patients before and after treatment.Results The total efficacy rate was 96.7% in the cervical jiaji point injection group and 93.3% in the electroacupuncture group.Serum ET content was higher and CGRP content was lower than the normal reference range in the two groups of patients before treatment.After treatment,serum ET content decreased to some extent,and CGRP content significantly increased compared with before treatment(P〈0.05).Conclusion ET and CGRP may play an important role in neurohumoral regulation in the development of vertebral artery-type cervical spondylopathy.Cervical jiaji point injection can more effectively decrease serum ET content,increase serum CGRP content,enlarge the inner diameter of vertebral artery and improve vertebroarterial blood flow.
出处 《上海针灸杂志》 2008年第2期14-16,共3页 Shanghai Journal of Acupuncture and Moxibustion
关键词 颈椎病 椎底动脉供血不足 水针 夹脊 Cervical spondylopathy Vertebrobasilar insufficiency Point injection Point,jiaji
  • 相关文献

参考文献3

  • 1第二届颈椎病专题座谈会纪要[J].中华外科杂志,1993,31(8):472-476. 被引量:2441
  • 2中华人民共和国卫生部.中药新药临床研究指导原则(第一辑)[S].,1993.103—106,91—94.
  • 3Yanagisawa M,Kurihara H,Kimura S,et al.A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J].Nature,1988,332(6163):411-415.

共引文献2468

同被引文献105

引证文献10

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部